Literature DB >> 21212379

How generalisable to community samples are clinical trial results for treatment of nicotine dependence: a comparison of common eligibility criteria with respondents of a large representative general population survey.

Yann Le Strat1, Jürgen Rehm, Bernard Le Foll.   

Abstract

OBJECTIVE: To examine the generalisability of findings from clinical trials of individuals with nicotine dependence to a large general population sample.
METHODS: Eligibility criteria were drawn from typical criteria of clinical trials for nicotine dependence. The National Epidemiological Survey on Alcohol and Related Conditions (NESARC), a large national sample of the US population, was used to assess how many potentially eligible people would fulfil the eligibility criteria. NESARC interviewed more than 43,000 adults aged 18 years and older. We applied a standard set of eligibility criteria representative of smoking cessation clinical trials to all the 4962 adults with nicotine dependence in the past 12 months, and then to a subgroup of participants motivated to quit (n=4121).
RESULTS: We found that approximately six out of 10 participants (65.89%) with nicotine dependence were excluded by at least one criterion. In the subgroup of nicotine-dependent participants motivated to quit, more than half (58.60%) were excluded by at least one criterion. For the overall sample, smoking 10 cigarettes per day or less and lack of motivation to quit were the two criteria leading to exclusion for the greatest percentage of individuals (32.02% and 17.60%, respectively). For the sample motivated to quit, smoking 10 cigarettes or fewer per day and current depression led most frequently to exclusion (33.79% and 15.71%, respectively).
CONCLUSIONS: Further studies and interventions should explore the efficacy of tobacco treatment interventions in a larger segment of the population, notably in the subpopulations of people with nicotine dependence who smoke fewer than 10 cigarettes per day or who have comorbid depression.

Entities:  

Mesh:

Year:  2011        PMID: 21212379     DOI: 10.1136/tc.2010.038703

Source DB:  PubMed          Journal:  Tob Control        ISSN: 0964-4563            Impact factor:   7.552


  30 in total

1.  Representativeness of patients enrolled in influential clinical trials: a comparison of substance dependence with other medical disorders.

Authors:  Keith Humphreys; Natalya C Maisel; Janet C Blodgett; John W Finney
Journal:  J Stud Alcohol Drugs       Date:  2013-11       Impact factor: 2.582

2.  Ten-year weight gain in smokers who quit, smokers who continued smoking and never smokers in the United States, NHANES 2003-2012.

Authors:  S Veldheer; J Yingst; J Zhu; J Foulds
Journal:  Int J Obes (Lond)       Date:  2015-07-09       Impact factor: 5.095

3.  Predicting Participation in Psychiatric Randomized Controlled Trials: Insights From the STEP-BD.

Authors:  Alisa B Busch; Yulei He; Katya Zelevinsky; Alistair J O'Malley
Journal:  Psychiatr Serv       Date:  2015-03-31       Impact factor: 3.084

4.  Generalizability of pharmacological and psychotherapy clinical trial results for borderline personality disorder to community samples.

Authors:  Nicolas Hoertel; Saioa López; Shuai Wang; Ana González-Pinto; Frédéric Limosin; Carlos Blanco
Journal:  Personal Disord       Date:  2015-01

5.  Assessment of individual differences in response to acute bupropion or varenicline treatment using a long-access nicotine self-administration model and behavioral economics in female rats.

Authors:  Theodore Kazan; Christopher L Robison; Nicole Cova; Victoria M Madore; Sergios Charntikov
Journal:  Behav Brain Res       Date:  2020-02-25       Impact factor: 3.332

Review 6.  Adherence to Pharmacological Smoking Cessation Interventions: A Literature Review and Synthesis of Correlates and Barriers.

Authors:  Lauren R Pacek; F Joseph McClernon; Hayden B Bosworth
Journal:  Nicotine Tob Res       Date:  2018-09-04       Impact factor: 4.244

7.  Estimation of Population Average Treatment Effects in the FIRST Trial: Application of a Propensity Score-Based Stratification Approach.

Authors:  Jeanette W Chung; Karl Y Bilimoria; Jonah J Stulberg; Christopher M Quinn; Larry V Hedges
Journal:  Health Serv Res       Date:  2017-08-21       Impact factor: 3.402

8.  Effectiveness of stop-smoking medications: findings from the International Tobacco Control (ITC) Four Country Survey.

Authors:  Karin A Kasza; Andrew J Hyland; Ron Borland; Ann D McNeill; Maansi Bansal-Travers; Brian V Fix; David Hammond; Geoffrey T Fong; K Michael Cummings
Journal:  Addiction       Date:  2012-08-14       Impact factor: 6.526

9.  Individual differences in responding to bupropion or varenicline in a preclinical model of nicotine self-administration vary according to individual demand for nicotine.

Authors:  Theodore Kazan; Sergios Charntikov
Journal:  Neuropharmacology       Date:  2019-01-03       Impact factor: 5.250

10.  Extent and reporting of patient nonenrollment in influential randomized clinical trials, 2002 to 2010.

Authors:  Keith Humphreys; Natalya C Maisel; Janet C Blodgett; Ingrid L Fuh; John W Finney
Journal:  JAMA Intern Med       Date:  2013-06-10       Impact factor: 21.873

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.